MedTrace Logo

Photodynamic Therapy in Treating Patients With Lung Cancer

NCT01668823 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2014-07-31

No results posted yet for this study

Summary

This phase I trial is studying the side effects and best dose of photodynamic therapy using HPPH in treating patients with lung cancer. Photodynamic therapy uses a drug, such as HPPH, that becomes active when it is exposed to a certain kind of light. When the drug is active, cancer cells are killed.

Conditions

  • Adenocarcinoma of the Lung
  • Large Cell Lung Cancer
  • Recurrent Non-small Cell Lung Cancer
  • Squamous Cell Lung Cancer
  • Stage 0 Non-small Cell Lung Cancer

Interventions

DRUG

HPPH

Given IV

DRUG

photodynamic therapy

Undergo photodynamic therapy with HPPH

PROCEDURE

therapeutic bronchoscopy

Undergo therapeutic bronchoscopy for endoscopic debridement

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Roswell Park Cancer Institute

    lead OTHER

Principal Investigators

  • Samjot Dhillon · Roswell Park Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2013-06-30
Completion
2014-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01668823 on ClinicalTrials.gov